<DOC>
	<DOCNO>NCT01525212</DOCNO>
	<brief_summary>The purpose study determine change baseline HCV Ribonucleic acid ( RNA ) Day 4 follow three day dose BMS-929075 chronically genotype subtype 1a 1b HCV infect subject</brief_summary>
	<brief_title>Multiple Ascending Dose Study BMS-929075 Hepatitis C Virus ( HCV ) Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Men woman , age 18 65 year , inclusive Subjects naive HCV treatment , define previous exposure Interferon ( IFN ) , Ribavirin ( RBV ) ; HCVspecific direct act antiviral experimental therapy HCV genotype 1a 1b HCV RNA viral load ≥ 100,000 IU/mL Have one following : ) Documented Fibrotest score ≤ 0.72 AST platelet ratio index ( APRI ) ≤ 2 ; ii ) Documented liver biopsy within 12 month precede Day 1 show absence cirrhosis Body Mass Index ( BMI ) 18.0 35.0 kg/m2 , inclusive Any significant acute chronic medical illness History adrenal gland disease , include limited adrenal insufficiency Cushing 's syndrome Current recent ( within 3 month study drug administration ) gastrointestinal disease Any major surgery within 4 week study drug administration Any gastrointestinal surgery could impact upon absorption study drug Positive hepatitis B surface antigen ( HBsAg ) Positive Human Immunodeficiency Virus ( HIV ) 1 and/or 2 antibody Smoking &gt; 10 cigarette per day Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) &gt; 5x upper limit normal ( ULN ) Total Bilirubin ≥ 1.5x ULN Hemoglobin &lt; 10 g/dL Platelets &lt; 75,000 cell/μL ALC ( absolute lymphocyte count ) &lt; 1000 cell/μL Creatinine clearance ( estimate method Cockcroft Gault ) less 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>